Work

Abstract P2-11-19: Estimating the long-term risk of recurrence in patients receiving HER2-targeted agents in HER2+ early-stage breast cancer (ESBC)

Year: 2022

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/1538-7445.sabcs21-p2-11-19

Authors: David L Veenstra, Nathaniel Hendrix, Chantal M Dolan, Kathryn A Fisher, Deepa Lalla, Nina Oestreicher, Adam Brufsky

Institutions: University of Washington, Harvard University, Puma Biotechnology (United States), University of California, San Francisco, Magee-Womens Hospital

Language: English

Topic: HER2/EGFR in Cancer Research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4220903442

Cites:

Cited by:

Related to: 10